![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Boston_H_color%5B33632%5D_edited.png)
Time
Feb 9, 2022 05:00 PM in Eastern Time (US and Canada)
Description
Biomarker based testing and precision medicine based approaches have become a standard to guide treatment decisions for metastatic non-small cell lung cancer (NSCLC) and are crucial even for early stage/resected patients. There are several barriers that prevent optimal testing for patients, but the discovery of novel molecular targets and subsequent development of targeted therapies make it critical to find ways to overcome these barriers. As treatment progresses, there is a potential to develop resistance mechanisms to commonly used targeted therapies; these new targets are identified by the integration of precision medicine. Additionally, further research has revealed differing features even with the EGFR mutation (e.g., exon 18 vs. 19) that warrant alternative treatment to improve care for patients. It is imperative for all members of the lung cancer treatment team (oncologists, pathologists, pharmacists, nurse practitioners, nurses, and physicians’ assistants) to understand this data and recognize the complexity of managing these patients using a precision medicine based approach in both first line and subsequent line therapies. At this webinar, learn clinical pearls needed to attain best outcomes for your patients with these mutations in a case-based conversation with expert faculty. This program is supported by an educational grant from Pfizer. More detailed information including continuing education credit information can be found at: https://cme.bu.edu/NSCLCpart3